Taken together, the results of this study demonstrated that (i) FOXM1 expression was high in AFP-positive HCC and (ii) the proteasome inhibitor carfilzomib suppressed FOXM1 expression and showed antitumor effects on AFP-positive HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.